Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 14:34 ET | Source: Robbins LLP

Robbins LLP Urges ATRA Stockholders to Contact the Firm for Information About the Class Action Against Atara Biotherapeutics, Inc.

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
April 20, 2026 16:30 ET | Source: Robbins LLP

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Gossamer Bio, Inc. (GOSS) Misled Investors Regarding the Viability of its PROSERA Study
April 20, 2026 16:29 ET | Source: Robbins LLP

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
April 20, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 10, 2026 14:06 ET | Source: Robbins LLP

Robbins LLP Reminds CORT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action

Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidat
April 06, 2026 14:32 ET | Source: Robbins LLP

ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Aldeyra Therapeutics, Inc. (ALDX) Misled Investors Regarding its Lead Drug Candidate
March 31, 2026 20:51 ET | Source: Robbins LLP

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
March 31, 2026 15:08 ET | Source: Robbins LLP

AQST Stockholders Have Rights – If You Lost Money Investing in Aquestive Therapeutics, Inc. Contact the Firm for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Aquestive Therapeutics, Inc. (AQST) Misled Investors Regarding Approval of Anaphylm
March 31, 2026 14:50 ET | Source: Robbins LLP

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Nektar Therapeutics (NKTR) Overstated the Prospects of its REZOLVE-AA Trial
March 30, 2026 12:41 ET | Source: Robbins LLP

IBRX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ImmunityBio, Inc. Securities Fraud Class Action

Robbins LLP is Investigating Allegations that ImmunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate